Intellia Therapeutics (NTLA) Set to Announce Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is set to release its earnings data before the market opens on Thursday, November 7th. Analysts expect Intellia Therapeutics to post earnings of ($1.37) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The company had revenue of $7.00 million during the quarter, compared to the consensus estimate of $19.68 million. During the same quarter in the prior year, the firm earned ($1.40) EPS. The business’s revenue for the quarter was down 48.5% compared to the same quarter last year. On average, analysts expect Intellia Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $15.43 on Wednesday. Intellia Therapeutics has a 52 week low of $13.95 and a 52 week high of $34.87. The stock has a market capitalization of $1.57 billion, a P/E ratio of -2.82 and a beta of 1.81. The stock’s fifty day moving average is $19.55 and its 200 day moving average is $22.34.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on NTLA. Royal Bank of Canada reiterated an “outperform” rating and issued a $54.00 target price on shares of Intellia Therapeutics in a research report on Thursday, September 19th. JPMorgan Chase & Co. decreased their target price on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Evercore ISI upgraded Intellia Therapeutics to a “strong-buy” rating in a research report on Friday, August 9th. Robert W. Baird decreased their target price on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Finally, Stifel Nicolaus decreased their target price on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday, September 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $59.13.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.